Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 2.02, 9.01 · 8-K

Waters Corp

WATNYSEEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On August 4, 2026, Waters Corporation announced its results of operations for the quarter ended July 4, 2026. A copy of the related press release is furnished as Exhibit 99.1 to this Form 8-K.…

Filed Aug 4, 2026Accepted Aug 4, 2026, 6:10 AM EDTCIK 1000697Accession 0001193125-26-331413
Share

Company context

Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide.

Current securities

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsAug 21, 2026
  2. 10-Q filingAug 11, 2026
  3. 144 filingAug 6, 2026
  4. 4 filingJul 2, 2026
  5. 4 filingJul 2, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition On August 4, 2026, Waters Corporation announced its results of operations for the quarter ended July 4, 2026. A copy of the related press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 (by filename) d163377dex991.htm

EX-99.1 2 d163377dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 For Immediate Release Contact: Caspar Tudor, Head of Investor Relations - (508) 482-3448 Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results Second Quarter 2026 Highlights Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses. Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments. Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew 4% on a prior year comparable basis, reflecting strong traction from commercial execution and operational improvements under the Company’s 180-day growth revitalization plan that drove a faster-than-expected acceleration to mid-single-digit growth. …

Open exhibit ↗